P
Probir Chakravarty
Researcher at Francis Crick Institute
Publications - 101
Citations - 7818
Probir Chakravarty is an academic researcher from Francis Crick Institute. The author has contributed to research in topics: Cancer cell & Tumor microenvironment. The author has an hindex of 37, co-authored 93 publications receiving 5749 citations. Previous affiliations of Probir Chakravarty include National Institutes of Health & Lincoln's Inn.
Papers
More filters
Journal ArticleDOI
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Böttcher,Eduardo Bonavita,Probir Chakravarty,Hanna Blees,Mar Cabeza-Cabrerizo,Stefano Sammicheli,Neil C. Rogers,Erik Sahai,Santiago Zelenay,Caetano Reis e Sousa +9 more
TL;DR: A cellular and molecular checkpoint for intratumoral cDC1 recruitment is revealed that is targeted by tumor-derived PGE2 for immune evasion and that could be exploited for cancer therapy.
Journal ArticleDOI
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay,Annemarthe G. van der Veen,Jan P. Böttcher,Kathryn J. Snelgrove,Neil C. Rogers,Sophie E. Acton,Probir Chakravarty,Maria Romina Girotti,Richard Marais,Sergio A. Quezada,Erik Sahai,Caetano Reis e Sousa +11 more
TL;DR: It is shown that the growth of tumors formed by mutant BrafV600E mouse melanoma cells in an immunocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tumor-promoting inflammation.
Journal ArticleDOI
GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.
Julie Helft,Jan P. Böttcher,Probir Chakravarty,Santiago Zelenay,Jatta Huotari,Barbara U. Schraml,Delphine Goubau,Caetano Reis e Sousa +7 more
TL;DR: It is demonstrated that CD11c(+)MHCII(+) BMDCs are in fact a heterogeneous group of cells that comprises conventional DCs and monocyte-derived macrophages, and have important implications for the interpretation of a vast array of data obtained with DC culture systems.
Journal ArticleDOI
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Jermaine Coward,Hagen Kulbe,Probir Chakravarty,David Leader,Vessela Vassileva,D. Andrew Leinster,Richard G. Thompson,Tiziana Schioppa,Jeffery Nemeth,Jessica Vermeulen,Naveena Singh,Norbert Avril,Jeffrey Cummings,Elton Rexhepaj,Karin Jirström,William M. Gallagher,Donal J. Brennan,Iain A. McNeish,Frances R. Balkwill +18 more
TL;DR: In this paper, the authors investigated whether inhibition of IL-6 has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network, and they combined pre-clinical and in silico experiments with a phase II clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.
Journal ArticleDOI
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Kellie A. Charles,Hagen Kulbe,Robin Soper,Monica Escorcio-Correia,Toby Lawrence,Anne Schultheis,Probir Chakravarty,Richard G. Thompson,George Kollias,John F. Smyth,Frances R. Balkwill,Thorsten Hagemann +11 more
TL;DR: It is concluded that chronic production of TNF-alpha in the tumor microenvironment increases myeloid cell recruitment in an IL-17-dependent manner that contributes to the tumor-promoting action of this proinflammatory cytokine.